Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsAntonio MARCHINI, Amit KULKARNI, Annabel GREWENIG, Jean ROMMELAERE, Tiina MARTTILA, Tiago FERREIRA
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of laminins and/or galectins as biomarker(s) for predicting the outcome of the treatment with oncolytic parvovirus H1 (H-1 PV) in a cancer patient.
Claims12
Use of a biomarker selected from the group consisting of laminin and/or galectin for predicting the outcome of the treatment with parvovirus H1 (H-1PV) of a patient suspected to suffer from a cancer.
A method of determining whether a patient suspected to suffer from cancer is a candidate for H-1PV therapy for said cancer comprising the step of subjecting a patient's biological sample to at least one assay to measure the presence of a biomarker selected from the group consisting of laminin and/or galectin.
A kit for predicting whether a patient suspected to suffer from cancer is a candidate for H-1PV therapy, which kit comprises:
- (a) means for measuring the level of a biomarker selected from the group consisting of laminins and/or galectins;
- and
- b) optionally, a label giving instructions for the use of said kit in predicting whether a patient suspected to suffer from cancer is a candidate for H-1PV therapy.
Dependencies are inferred from the claim text.